$0.71
+0.05 (+7.31%)
Open$0.69
Previous Close$0.66
Day High$0.72
Day Low$0.67
52W High$3.07
52W Low$0.48
Volume—
Avg Volume3.31M
Market Cap218.01M
P/E Ratio—
EPS$-0.36
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+2,937.3% upside
Current
$0.71
$0.71
Target
$21.48
$21.48
$15.01
$21.48 avg
$34.49
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 95.63M | 178.19M | 160.29M |
| Net Income | -93,961,108 | 4.92M | 3.11M |
| Profit Margin | -98.3% | 2.8% | 1.9% |
| EBITDA | -98,091,944 | 6.39M | 5.91M |
| Free Cash Flow | — | 2.75M | 2.88M |
| Rev Growth | — | +11.2% | +5.5% |
| Debt/Equity | — | 0.18 | 0.17 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |